Fenbendazole MarketSize and Trends

Fenbendazole Market Driver

Increasing research and development activities for enhancing the efficiency of fenbendazole in treating various diseases in animals and humans is a major factor boosting growth of the fenbendazole market. For instance, in August 2018, researchers from National Centre for Human Genome Studies and Research (NCHGSR), India, reported that fenbendazole has potential to act as an effective anti-cancer agent. Fenbendazole can also be effective remedy in evading drug resistance commonly encountered in cancer therapy. To study this, researchers first treated human non-small cell lung cancer cells with fenbendazole and found tumor cell death.

Since, developing a promising molecule into an approved drug often consume considerable time and cost, repurposing of veterinary drugs in treating diseases in humans can be effective and have shown promising results and is expected to show cost reduction without need to develop new drugs.

Furthermore, approval of new fenbendazole drugs is expected to drive growth of the fenbendazole market. For instance, in January 2018, Merck Animal Health received approval from U.S. Food and Drug Administration (USFDA), for its Safe-Guard AquaSol, a fenbendazole oral suspension used in the treatment and control of adult Ascaridia galli in broiler chickens and Heterakis gallinarum in breeding chickens via drinking water. Safe-Guard AquaSol is produced with an innovative wet-milling technology, which produces a highly stable suspension that can be conveniently administered to hens through drinking water.